CA
NZ
UK
AU
IND
US
…
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
| Income before tax | -1.60M | -7.35M | -2.19M | -1.69M | 0.00M |
| Minority interest | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income | -1.60M | -7.35M | -2.19M | -1.69M | 0.00M |
| Selling general administrative | 0.37M | 2.91M | 1.03M | 0.72M | 0.00M |
| Gross profit | 0.00M | 0.14M | 0.04M | 0.01M | 0.00M |
| Ebit | -7.94M | -9.16M | -8.30M | -6.18M | 0.00M |
| Non operating income net other | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Operating income | -0.99M | -7.26M | -2.24M | -1.52M | 0.00M |
| Other operating expenses | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Extraordinary items | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Non recurring | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other items | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.01M | 0.22M | 0.07M | 0.02M | 0.15M |
| Total operating expenses | 0.99M | 7.48M | 2.30M | 1.54M | 0.00M |
| Cost of revenue | 0.00M | 0.08M | 0.02M | 0.01M | 3.64M |
| Total other income expense net | -0.62M | -0.09M | 0.05M | -0.17M | 0.00M |
| Discontinued operations | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income from continuing ops | -1.60M | -7.35M | -2.19M | -1.69M | 0.00M |
| Net income applicable to common shares | -12.94M | -9.27M | -8.11M | -6.86M | 0.00M |
| Preferred stock and other adjustments | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Breakdown | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
| Total assets | 0.89M | 4.85M | 4.43M | 3.63M | 3.94M |
| Intangible assets | 0.00M | 0.00M | 0.16M | 0.13M | 0.39M |
| Other current assets | 0.00M | 0.00M | 0.00M | 0.00M | 0.06M |
| Total liab | 1.72M | 3.54M | 1.41M | 1.51M | 5.39M |
| Total stockholder equity | -0.83M | 1.31M | 3.02M | 2.12M | 0.00M |
| Deferred long term liab | 0.00M | 0.00M | 0.36M | 0.18M | 0.00M |
| Other current liab | 0.17M | 0.03M | 0.04M | 0.04M | 0.24M |
| Common stock | 50.61M | 49.88M | 49.88M | 39.90M | 19.42M |
| Retained earnings | -66.80M | -53.86M | -43.97M | -35.85M | 0.00M |
| Other liab | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Good will | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other assets | 0.00M | 0.00M | 0.36M | 0.18M | 0.29M |
| Cash | 0.47M | 2.25M | 1.09M | 1.14M | 0.75M |
| Total current liabilities | 11.91M | 1.92M | 1.94M | 4.25M | 3.36M |
| Short term debt | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Short long term debt | 1.26M | 0.42M | 0.16M | 0.12M | 0.00M |
| Short long term debt total | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Other stockholder equity | 3.67M | 0.00M | 0.00M | 0.00M | 0.00M |
| Property plant equipment | 1.84M | 2.20M | 2.46M | 2.58M | 2.25M |
| Total current assets | 5.36M | 3.92M | 13.03M | 11.42M | 0.00M |
| Long term investments | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net tangible assets | -6.66M | 1.66M | 10.61M | 8.04M | 0.00M |
| Short term investments | 0.00M | 0.00M | 2.13M | 1.54M | 0.00M |
| Net receivables | 1.34M | 0.89M | 0.85M | 0.30M | 0.00M |
| Long term debt | 0.24M | 2.02M | 0.89M | 0.46M | 2.04M |
| Inventory | 0.06M | 0.02M | 0.01M | 0.00M | 0.01M |
| Accounts payable | 0.50M | 0.65M | 0.58M | 0.48M | 0.32M |
| Total permanent equity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Noncontrolling interest in consolidated entity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Temporary equity redeemable noncontrolling interests | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Accumulated other comprehensive income | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Additional paid in capital | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Common stock total equity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Treasury stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Accumulated amortization | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Non currrent assets other | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Deferred long term asset charges | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Capital lease obligations | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Long term debt total | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Breakdown | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2009-03-31 | 2008-03-31 | 2007-03-31 | 2006-03-31 | 2005-03-31 |
| Investments | 0.00M | 7.89M | -1.64M | -6.25M | 0.00M |
| Change to liabilities | -0.05M | 0.02M | -0.25M | 0.32M | 0.11M |
| Total cashflows from investing activities | -0.23M | 7.77M | -1.98M | -6.51M | 0.57M |
| Net borrowings | 11.96M | -0.57M | -1.02M | -0.21M | 0.00M |
| Total cash from financing activities | 10.76M | -0.58M | 8.91M | 16.42M | 1.89M |
| Change to operating activities | 0.02M | 0.07M | -0.03M | -1.22M | 0.00M |
| Net income | -12.94M | -9.27M | -8.11M | -6.86M | 0.00M |
| Change in cash | 0.97M | -1.20M | -0.60M | 3.74M | 0.00M |
| Total cash from operating activities | -9.57M | -8.39M | -7.52M | -6.17M | 0.00M |
| Depreciation | 0.36M | 0.38M | 0.41M | 0.37M | 0.00M |
| Other cashflows from investing activities | 0.00M | 0.00M | -0.10M | -0.09M | 0.00M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | -0.04M | -0.01M | -0.01M | 0.01M | 0.00M |
| Change to account receivables | -0.06M | -0.01M | -0.06M | 0.02M | 0.00M |
| Sale purchase of stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | -1.20M | -0.02M | -1.07M | -0.66M | 0.00M |
| Change to netincome | 3.08M | 0.36M | 0.48M | 0.99M | 0.00M |
| Capital expenditures | 0.23M | 0.12M | 0.25M | 0.17M | 0.04M |
| Change receivables | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Cash flows other operating | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Exchange rate changes | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Cash and cash equivalents changes | 0.00M | 0.00M | 0.00M | 0.00M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.
| Name | Title | Year Born |
|---|---|---|
| Dr. Amine Selmani Ph.D. | Founder & Advisor | 1957 |
| Dr. Alberto Restrepo M.D. | Director of Medical Affairs | NA |
| Ms. Catherine Auld C.A. | Chief Financial Officer | NA |
| Ms. Lucie Duval | Controller | 1959 |
| Ms. Lucie Duval B.A.A | Controller | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...